Loss of the Tumor Suppressor HACE1 Contributes to Cancer Progression

Author(s): Jun-Chen Li, Xing Chang, Yang Chen, Xin-Zhe Li, Xiang-Lian Zhang, Shi-Ming Yang, Chang-Jiang Hu*, Hao Zhang*.

Journal Name: Current Drug Targets

Volume 20 , Issue 10 , 2019

Submit Manuscript
Submit Proposal

Abstract:

HACE1 belongs to the family of HECT domain-containing E3 ligases, which plays an important role in the occurrence, invasion and metastatic process in many human malignancies. HACE1 is a tumor suppressor gene that is reduced in most cancer tissues compared to adjacent normal tissue. The loss or knocking out of HACE1 leads to enhanced tumor growth, invasion, and metastasis; in contrast, the overexpression of HACE1 can inhibit the development of tumors. Hypermethylation reduces the expression of HACE1, thereby promoting tumor development. HACE1 can inhibit the development of inflammation or tumors via the ubiquitination pathway. Therefore, HACE1 may be a potential therapeutic target, providing new strategies for disease prevention and treatment.

Keywords: HECT domain and ankyrin repeat containing, E3 ubiquitin protein ligase 1 (HACE1), tumor suppressor, methylation, ubiquitylation, RAC1.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 10
Year: 2019
Page: [1018 - 1028]
Pages: 11
DOI: 10.2174/1389450120666190227184654
Price: $95

Article Metrics

PDF: 30